CD8A and hepatocellular carcinoma: A previous study with 10 HCC has linked lower baseline levels of peripheral blood PD‐1+B cell and PD‐L1+ monocytes to better disease control of ICI,[29] and highly activated circulating CD8+ T cells during pembrolizumab treatment to clinical benefit[30] in HCC.